Sign In
Buy PHIO
$1.03
-0.0050 (-0.485%)
At Close: Jul 31, 2026
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)
02:52am, Friday, 27'th Mar 2026
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contr
Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)
02:19am, Friday, 27'th Mar 2026
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two b
Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT) King of Prussia, Pennsylvania--(Newsfile Corp. - Ma
Phio Pharmaceuticals (PHIO) Projected to Post Earnings on Monday
01:42am, Monday, 23'rd Mar 2026
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.3
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
11:30am, Monday, 16'th Mar 2026
Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
08:35am, Tuesday, 10'th Mar 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
07:59am, Tuesday, 10'th Mar 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
07:00am, Tuesday, 10'th Mar 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
04:05pm, Thursday, 05'th Mar 2026
Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance She
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
07:00am, Thursday, 05'th Mar 2026
Live Presentation and Q&A: Monday, March 9, 2026 10 AM EDT CEO to Discuss INTASYL Platform and PH-762 Phase 1b Results King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceut
What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?
08:43am, Thursday, 12'th Feb 2026
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) stock is trading lower on Thursday; however, there is no news to justify the movement. The stock could possibly be down on profit-taking after the stock close
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients
11:12am, Tuesday, 10'th Feb 2026
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares are up on Tuesday' as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762.
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
07:00am, Tuesday, 10'th Feb 2026
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 Responders No Serious Adverse Events or Dose-Limiting
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
08:15am, Monday, 26'th Jan 2026
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ET King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, Pen
